Paid Clinical Trials for Head and Neck Squamous Cell Carcinoma

in Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV

Other

California

Deadline:

03/01/2029

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

by CTG

in Head and Neck Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Hypopharyngeal Squamous Cell Carcinoma

Other

Arizona

Deadline:

01/01/2027

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR – HN1)

by CTG

in Head and Neck Squamous Cell Carcinoma

Other

Alabama

Deadline:

07/01/2030

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

by CTG

in Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Larynx Cancer, Oropharynx Cancer, Oral Cavity Cancer

Other

Missouri

Deadline:

03/30/2028

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

by CTG

in Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Radiotracer, SCC - Squamous Cell Carcinoma

Other

Tennessee

Deadline:

04/01/2031

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

by CTG

in Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Metastatic Colorectal Carcinoma

Other

California

Deadline:

05/12/2028

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

by CTG

in Head and Neck Squamous Cell Carcinoma

Other

Kentucky

Deadline:

07/31/2027

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

by CTG

in Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Recurrent Gallbladder Carcinoma, Non-Resectable Cholangiocarcinoma

Other

California

Deadline:

04/01/2026

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

by CTG

in Head and Neck Squamous Cell Carcinoma, Melanoma

Other

New York

Deadline:

12/01/2026

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

by CTG

in Colorectal Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer Metastatic, Esophageal Squamous Cell Carcinoma

Other

California

Deadline:

03/01/2027

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

by CTG

in Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Unknown Primary Cancer

Other

Texas

Deadline:

12/31/2027

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status.

by CTG

in Head and Neck Squamous Cell Carcinoma

Other

Missouri

Deadline:

08/01/2026

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

by CTG

in Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma of Unknown Primary, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC V8, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Hypopharyngeal Squamous Cell Carcinoma

Other

Georgia

Deadline:

10/31/2029

Load more All clinical trials loaded.

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

A Study of NX-1607 in Adults With Advanced Malignancies

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR – HN1)

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status.

Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Head and Neck Squamous Cell Carcinoma

Filter Results:

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps